✓ verified = confirmed by human source
◇ research = AI-assisted, pending confirmation
Status◇ research
Acquired
Exit Type◇ research
Acquisition
Subsequent Funding◇ research
$0
Received VC Funding◇ research
No
Current Employees◇ research
—
Peak Employees◇ research
—
SBIR/STTR Awards◇ research
$599,888
Used Crowdfunding◇ research
No
Exit Valuation◇ research
$13,300,000
Notes
Vindico NanoBioTechnology looks like a clear early bioscience exit. Kentucky records show completed 2015 KAITC investment, SEC merger materials document the October 10, 2016 merger with Poseida, and transaction coverage places the deal value at about $13.3 million.
[Deep research 2026-04-11] Additional funding details: Received Gates Foundation award via Grand Challenges Explorations (amount/date unspecified) and $299,683 National Heart, Lung and Blood Institute/KY Cabinet award. SBIR funding confirmed at $599,888 across 2 NIH grants in 2011, including project integrating Toll-like receptor 7/8 agonist resiquimod into polymersomes. Received eAchiever award from Lexington Venture Club. Part of $1.8M state high-tech funding pool for seven firms, focused on synthetic blood substitute development. Key personnel included Eric Ostertag (seller in acquisition) and John R. Hall (listed in 2015 investment records).
Last updated: Apr 11, 2026 · Evidence score: 5/5